Summary of Study ST000787

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000574. The data can be accessed directly via it's Project DOI: 10.21228/M8GD58 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST000787
Study TitleIdentifying metabolic adaptations characteristic of multiple myeloma cells via mass spectrometry-based metabolite profiling from Peripheral Plasma
Study SummaryWill be assessing the untargeted metabolomic profiles of high risk versus low risk smoldering myeloma patients based on peripheral blood plasma, bone marrow plasma and Cd138+ plasma cells. Peripheral Plasma ms5972
Institute
Mayo Clinic
Last NameGonsalves
First NameWilson
Address200 First St. SW, Rochester, Minnesota, 55905, USA
Emailgonsalves.wilson@mayo.edu
Phone507-266-0792
Submit Date2017-07-11
Analysis Type DetailLC-MS
Release Date2019-07-17
Release Version1
Wilson Gonsalves Wilson Gonsalves
https://dx.doi.org/10.21228/M8GD58
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000574
Project DOI:doi: 10.21228/M8GD58
Project Title:Mayo Pilot and Feasibility: Identifying metabolic adaptations characteristic of multiple myeloma cells via mass spectrometry-based metabolite profiling
Project Summary:Multiple myeloma (MM) is a clonal plasma cell malignancy that remains incurable in most afflicted patients. It can be preceded by an asymptomatic, premalignant stage known as smoldering multiple myeloma (SMM) that does not require therapy but has an increased life-long risk of progression to MM. However, one-third of SMM patients are “high risk” for imminent progression to MM within two years of diagnosis compared to the remainder of SMM patients who continue on an indolent asymptomatic course for several years. The diagnosis of MM cannot be made until they experience overt end-organ damage such as renal failure, lytic bone destruction, anemia and hypercalcemia. Currently, we lack sensitive biomarkers that can identify all SMM patients at high risk of progression to MM. Being able to identify high risk SMM patients could allow us to initiate systemic chemotherapy before they progress to MM. Cancer cells undergo distinct metabolic adaptations to meet the augmented cellular demand for energy and nutrients created by their increased rates of cellular proliferation. The presence of an altered cellular metabolism in clonal PCs from MM patients and its role as an essential factor in the progression of SMM to MM is unknown. We hypothesize that the clonal PCs in high risk SMM patients likely have an altered metabolic phenotype similar to those present in MM patients but different when compared to clonal PCs in the remainder of the SMM patients whose clinical course remains indolent. Thus, two specific aims are proposed in this study: Aim 1 will verify if there are differences in the regulation of the metabolic pathways in clonal PCs from MM patients compared to normal PCs from healthy patients; Aim 2 will assess whether the clonal PCs from high risk SMM patients bear a distinct metabolic phenotype compared to clonal PCs from standard risk SMM patients.
Institute:Mayo Clinic
Last Name:Gonsalves
First Name:Wilson
Address:200 First St. SW, Rochester, Minnesota, 55905, USA
Email:gonsalves.wilson@mayo.edu
Phone:507-266-0792

Subject:

Subject ID:SU000812
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id groups
SA043157philic-12jan16-02-r001Quick Progressors
SA043158nhilic-13jan16-24Quick Progressors
SA043159nhilic-13jan16-20Quick Progressors
SA043160philic-12jan16-02-r002Quick Progressors
SA043161nhilic-13jan16-22Quick Progressors
SA043162philic-12jan16-03-r002Quick Progressors
SA043163philic-12jan16-07-r001Quick Progressors
SA043164philic-12jan16-05-r002Quick Progressors
SA043165philic-12jan16-05-r001Quick Progressors
SA043166nhilic-13jan16-19Quick Progressors
SA043167philic-12jan16-03-r001Quick Progressors
SA043168nhilic-13jan16-17Quick Progressors
SA043169nhilic-13jan16-07Quick Progressors
SA043170nhilic-13jan16-05Quick Progressors
SA043171nhilic-13jan16-03Quick Progressors
SA043172nhilic-13jan16-02Quick Progressors
SA043173nhilic-13jan16-09Quick Progressors
SA043174nhilic-13jan16-11Quick Progressors
SA043175nhilic-13jan16-16Quick Progressors
SA043176nhilic-13jan16-15Quick Progressors
SA043177nhilic-13jan16-12Quick Progressors
SA043178philic-12jan16-07-r002Quick Progressors
SA043179philic-12jan16-09-r002Quick Progressors
SA043180philic-12jan16-19-r002Quick Progressors
SA043181philic-12jan16-19-r001Quick Progressors
SA043182philic-12jan16-17-r002Quick Progressors
SA043183philic-12jan16-17-r001Quick Progressors
SA043184philic-12jan16-20-r001Quick Progressors
SA043185philic-12jan16-20-r002Quick Progressors
SA043186philic-12jan16-24-r002Quick Progressors
SA043187philic-12jan16-24-r001Quick Progressors
SA043188philic-12jan16-22-r002Quick Progressors
SA043189philic-12jan16-22-r001Quick Progressors
SA043190philic-12jan16-16-r002Quick Progressors
SA043191philic-12jan16-16-r001Quick Progressors
SA043192philic-12jan16-12-r001Quick Progressors
SA043193philic-12jan16-11-r002Quick Progressors
SA043194philic-12jan16-11-r001Quick Progressors
SA043195pC18-12jan16-24Quick Progressors
SA043196philic-12jan16-12-r002Quick Progressors
SA043197philic-12jan16-13-r001Quick Progressors
SA043198philic-12jan16-15-r002Quick Progressors
SA043199philic-12jan16-15-r001Quick Progressors
SA043200philic-12jan16-13-r002Quick Progressors
SA043201philic-12jan16-09-r001Quick Progressors
SA043202nhilic-13jan16-13Quick Progressors
SA043203pC18-12jan16-07Quick Progressors
SA043204nC18-13jan16-13Quick Progressors
SA043205pC18-12jan16-05Quick Progressors
SA043206nC18-13jan16-12Quick Progressors
SA043207nC18-13jan16-11Quick Progressors
SA043208nC18-13jan16-07Quick Progressors
SA043209pC18-12jan16-11Quick Progressors
SA043210pC18-12jan16-09Quick Progressors
SA043211nC18-13jan16-15Quick Progressors
SA043212nC18-13jan16-16Quick Progressors
SA043213nC18-13jan16-20Quick Progressors
SA043214nC18-13jan16-24Quick Progressors
SA043215nC18-13jan16-22Quick Progressors
SA043216nC18-13jan16-19Quick Progressors
SA043217nC18-13jan16-17Quick Progressors
SA043218pC18-12jan16-03Quick Progressors
SA043219pC18-12jan16-02Quick Progressors
SA043220pC18-12jan16-12Quick Progressors
SA043221nC18-13jan16-09Quick Progressors
SA043222pC18-12jan16-16Quick Progressors
SA043223pC18-12jan16-15Quick Progressors
SA043224nC18-13jan16-05Quick Progressors
SA043225pC18-12jan16-17Quick Progressors
SA043226nC18-13jan16-03Quick Progressors
SA043227pC18-12jan16-13Quick Progressors
SA043228pC18-12jan16-19Quick Progressors
SA043229pC18-12jan16-20Quick Progressors
SA043230nC18-13jan16-02Quick Progressors
SA043231pC18-12jan16-22Quick Progressors
SA043232nC18-13jan16-21Slow Progressors
SA043233philic-12jan16-14-r002Slow Progressors
SA043234philic-12jan16-25-r002Slow Progressors
SA043235nC18-13jan16-18Slow Progressors
SA043236philic-12jan16-25-r001Slow Progressors
SA043237philic-12jan16-14-r001Slow Progressors
SA043238philic-12jan16-23-r001Slow Progressors
SA043239philic-12jan16-10-r002Slow Progressors
SA043240nC18-13jan16-08Slow Progressors
SA043241philic-12jan16-21-r002Slow Progressors
SA043242philic-12jan16-21-r001Slow Progressors
SA043243nC18-13jan16-06Slow Progressors
SA043244nC18-13jan16-10Slow Progressors
SA043245philic-12jan16-23-r002Slow Progressors
SA043246nC18-13jan16-14Slow Progressors
SA043247philic-12jan16-18-r001Slow Progressors
SA043248philic-12jan16-18-r002Slow Progressors
SA043249nC18-13jan16-04Slow Progressors
SA043250philic-12jan16-06-r002Slow Progressors
SA043251nhilic-13jan16-14Slow Progressors
SA043252nC18-13jan16-01Slow Progressors
SA043253pC18-12jan16-14Slow Progressors
SA043254nhilic-13jan16-18Slow Progressors
SA043255nhilic-13jan16-21Slow Progressors
SA043256pC18-12jan16-10Slow Progressors
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 125

Collection:

Collection ID:CO000806
Collection Summary:In order to analyze the metabolites of clonal PCs (intracellular) and BM plasma (extracellular) separately, they have to be separated out from the BM samples. Thus, upon acquiring the BM samples from patients they will be placed in centrifuged at 2500 rpm for 10 minutes to separate out the plasma from the cellular fraction. The separated BM plasma is then stored in separate vials and snap frozen under liquid nitrogen for 20 seconds before storing at -80οC for further analysis. The leftover cellular component present as a pellet will be washed and reconstituted with an equal volume of RPMI 1640 medium. Erythrocytes are lysed using ammonium chloride lysing solution. After incubation on ice for 5 min, the cell suspension is diluted with RPMI medium. The cells are again pelleted by centrifugation and then suspended in RoboSep buffer (250ml PBS, 2% BSA, 1mM EDTA). The clonal CD138 positive PCs are purified using positive selection by mixing the cells with a CD138 positive selection cocktail and anti-CD138 magnetic-activated cell separation microbeads (ROBOSEP™ cell separation system, StemCell Technologies Inc) in the automated RoboSep cell separation system. The purified samples containing only CD138 positive cells are re‐suspended and then centrifuged to form a cell pellet. The goal will be to obtain at least 1-2 x 107 clonal PCs per sample. The cell pellet will be snap frozen under liquid nitrogen for 20 seconds before storing at -80οC for further analysis. Both the BM plasma samples as well as the clonal PCs pellet will be provided to the metabolomics core for sample preparation for LC-MS analysis. For Aim 2, we will be using stored BM samples from SMM patients that have already had their BM plasma and clonal PCs separated from each other and stored at -80οC. It is important to note that all these samples were collected and frozen in a timely manner. Furthermore consistency in sample collection, storage and processing is imperative for the optimal conduct of metabolomics-based experiments. This ensures that all samples being analyzed and compared with each other would have been manipulated similarly, limiting any handling biases. All patient samples in the Predolin Foundation Biobank were collected and stored by following a standardized operating procedure. BM samples were processed for BM plasma separation and clonal PCs enrichment but were then immediately snap frozen for storage at -80οC within approximately 3 hours of collection from the patient. All samples were collected in patients who have been fasting for at least 6 to 8 hours prior. To further ensure consistency in our analysis of this study, we will only use samples that have never been thawed since initial storage to preserve the stability of the metabolites originally present in the samples.
Sample Type:Bone marrow

Treatment:

Treatment ID:TR000826
Treatment Summary:We will use matched BM plasma and purified clonal marrow PCs from the BM samples of SMM patients collected at the time of their diagnosis and stored within the Mayo Clinic Predolin Foundation Biobank. We will select BM samples from patients with SMM who progressed to MM within 2 years of their samples being collected and stored; this will constitute the high risk SMM group. We will also select BM samples from SMM patients who have not progressed to MM within at least 2 years of follow up of their samples being collected and stored; this will constitute the standard risk SMM group. The strength of this approach is that we will utilize stored SMM samples from one of the most comprehensively characterized monoclonal gammopathy biobanks available. Secondly, all samples will be obtained from collection dates at least 2 years prior in order to ensure adequate follow-up time to assess their current clinical status. This would avoid the need to prospectively collect samples from SMM patients and clinically follow them for a number of years before we are able to gauge who were clinically high or standard risk for progression. There are over 700 SMM patients who have had their BM samples collected and stored in the biobank from 1996 to 2013; more than half these patients have progressed to MM.

Sample Preparation:

Sampleprep ID:SP000819
Sampleprep Summary:The metabolite profiling as well as sample preparations will be undertaken at the Mayo Clinic Metabolomics Resource Core. The matched BM plasma and clonal PCs pellets from the stored patient samples will undergo metabolite extraction and analysis by LC-MS. They will be deproteinized with cold methanol (1:4 ratio) and centrifuged at 15,000 g for 20 minutes at 4οC. The supernatants will be divided into 2 aliquots and dried down under a stream of nitrogen for 90 minutes and stored at -20C until ready for analysis. These samples will undergo preparation for metabolite separation and analysis on a Time-of-Flight (TOF) Mass Spectrometer (Agilent Technologies 6220 TOF) coupled with an Ultra High Pressure Liquid Chromatograph (Waters Acquity). The dried metabolites will be re‐suspended in H2O/acetonitrile solution containing injection standards. Profiling data will be acquired under both positive and negative electrospray ionization modes separately over a scan range of 50 - 1200 m/z at a resolution of 10,000. Metabolite separation will be achieved using two columns of differing polarity, a hydrophilic interaction column (HILIC, ethylene-bridged hybrid 2.1 x 150 mm, 1.7 mm; Waters) and a reversed-phase C18 column (high-strength silica 2.1 x 150 mm, 1.8 mm; Waters). For positive ion detection, mobile phase A will contain 100% water with 0.1% formic acid and mobile phase B will contain 100% methanol with 0.1% formic acid. For negative ion detection, formic acid will be replaced with 0.1% ammonium bicarbonate. For each column, the run time will be 20 min using a flow rate of 400 microL/min. A total of four runs per sample will be performed to give maximum coverage of metabolites. Samples will be injected in triplicate with blank injections between samples. Quality control samples, made up of a subset of samples from the study will be injected several times during a run.

Combined analysis:

Analysis ID AN001246 AN001247 AN001248 AN001249
Analysis type MS MS MS MS
Chromatography type Reversed phase Reversed phase HILIC HILIC
Chromatography system Agilent 1290 Infinity Agilent 1290 Infinity Agilent 1290 Infinity Agilent 1290 Infinity
Column Waters Acquity HSS C18 (150 x 2.1mm,1.8um) Waters Acquity HSS C18 (150 x 2.1mm,1.8um) Waters Acquity BEH Amide (150 x 2.1mm,1.7um) Waters Acquity BEH Amide (150 x 2.1mm,1.7um)
MS Type ESI ESI ESI ESI
MS instrument type QTOF QTOF QTOF QTOF
MS instrument name Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF
Ion Mode POSITIVE NEGATIVE POSITIVE NEGATIVE
Units intensity intensity intensity intensity

Chromatography:

Chromatography ID:CH000870
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity HSS C18 (150 x 2.1mm,1.8um)
Chromatography Type:Reversed phase
  
Chromatography ID:CH000871
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity BEH Amide (150 x 2.1mm,1.7um)
Chromatography Type:HILIC

MS:

MS ID:MS001139
Analysis ID:AN001246
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:POSITIVE
  
MS ID:MS001140
Analysis ID:AN001247
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:NEGATIVE
  
MS ID:MS001141
Analysis ID:AN001248
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:POSITIVE
  
MS ID:MS001142
Analysis ID:AN001249
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:NEGATIVE
  logo